RogCon

California, United States Founded: 2016 • Age: 10 yrs
Developer of small molecule based therapeutics for the treatment of neurological disorders

About RogCon

RogCon is a company based in United States founded in 2016 by Alex Nemiroff and Kelley Dalby.. RogCon has raised $1.14 million across 1 funding round. RogCon operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.

  • Headquarter California, United States
  • Founders Alex Nemiroff, Kelley Dalby
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Rogcon, Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.14 M (USD)

    in 1 rounds

  • Latest Funding Round
    $1.14 M (USD), Seed

    Apr 03, 2017

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of RogCon

RogCon has successfully raised a total of $1.14M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.14 million completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $1.1M
  • First Round

    (03 Apr 2017)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2017 Amount Seed - RogCon Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by RogCon

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - RogCon

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Rogcon Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of RogCon

RogCon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Drugs for CNS disorders are developed and advanced.
domain founded_year HQ Location
Developer of therapeutic solutions for the treatment of diabetes
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
domain founded_year HQ Location
Therapies for neurological and neuropsychiatric diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Rogcon

Frequently Asked Questions about RogCon

When was RogCon founded?

RogCon was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is RogCon located?

RogCon is headquartered in United States. It is registered at California, United States.

Who is the current CEO of RogCon?

Alex Nemiroff is the current CEO of RogCon. They have also founded this company.

Is RogCon a funded company?

RogCon is a funded company, having raised a total of $1.14M across 1 funding round to date. The company's 1st funding round was a Seed of $1.14M, raised on Apr 03, 2017.

What does RogCon do?

RogCon is developing small molecule-based therapeutics for the treatment of neurological disorders such as epilepsy, autism, etc. The company has developed product candidates targeting SCN2A mutations which has completed its pre-clinical trials.

Who are the top competitors of RogCon?

RogCon's top competitors include Jazz Pharmaceuticals, Biohaven Pharmaceutical and Sana Biotechnology.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available